BiotechTube

Pemvidutide

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Liver Disease

Conditions

Alcohol Liver Disease

Trial Timeline

Jun 16, 2025 → Aug 31, 2027

NCT ID
NCT07009860

About Pemvidutide

Pemvidutide is a phase 2 stage product being developed by Altimmune for Alcohol Liver Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07009860. Target conditions include Alcohol Liver Disease.

What happened to similar drugs?

11 of 20 similar drugs in Alcohol Liver Disease were approved

Approved (11) Terminated (2) Active (8)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅Selincro® 18 mg with continuous psychosocial support: Cohort ALundbeckApproved
✅nalmefeneLundbeckApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07009860Phase 2Recruiting
NCT06987513Phase 2Active

Competing Products

20 competing products in Alcohol Liver Disease

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
Mazdutide + PlaceboEli LillyPhase 2
42
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35